文献速递医学人工智能与信息学临床试验与 GCP

机器学习在前列腺癌根治性放疗中的临床整合

Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer.
PubMed 文献 · Nat Med · 2021-06-03

本研究将随机森林算法用于前列腺癌根治性放疗计划制定,通过回顾性模拟(n=50)和前瞻性临床部署(n=50)两阶段盲法头对头比较机器学习与人工生成的放疗计划。结果显示89%的机器学习计划临床可接受,72%在头对头比较中被选中,放疗计划全程中位时间缩短60.1%(118至47小时),但前瞻性阶段机器学习计划被选用于治疗的比例显著低于模拟阶段(61% vs 83%)。

要点

  • 机器学习生成的放疗计划89%临床可接受,72%在头对头比较中被选中
  • 机器学习使放疗计划全程中位时间缩短60.1%(118至47小时)
  • 前瞻性部署阶段机器学习计划被选用于治疗的比例显著低于模拟阶段(61% vs 83%)

核心结论

  • 机器学习生成的前列腺癌根治性放疗计划多数临床可接受且可缩短计划时间,但模拟或回顾性评估可能高估其在真实临床中的接受度。

研究设计与样本

  • 前瞻性部署随机森林算法用于前列腺癌根治性放疗计划制定,并整合入临床工作流程。
  • 采用盲法头对头研究,分回顾性模拟与重测阶段(n=50)和前瞻性临床部署阶段(n=50)。
  • 治疗医生按预先定义的标准化标准和同行评审流程盲法评估机器学习与人工生成的放疗计划。

主要发现

  • 89%的机器学习生成放疗计划被评估为临床可接受。
  • 72%的机器学习计划在头对头比较中被选中优于人工生成计划。
  • 机器学习使放疗计划全程中位时间缩短60.1%(118至47小时)。
  • 机器学习计划可接受率在模拟与部署阶段保持稳定(92% vs 86%)。
  • 机器学习计划被选用于治疗的比例在部署阶段显著低于模拟阶段(61% vs 83%)。

临床怎么用

  • 机器学习可用于前列腺癌根治性放疗计划制定以缩短计划时间,但需在前瞻性临床部署中验证其真实接受度。

局限性

  • 回顾性或模拟评估方法,即使在专家盲法评审下,也可能不能代表真实临床场景中算法被接受的程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Machine learning (ML) holds great promise for impacting healthcare delivery; however, to date most methods are tested in 'simulated' environments that cannot recapitulate factors influencing real-world clinical practice. We prospectively deployed and evaluated a random forest algorithm for therapeutic curative-intent radiation therapy (RT) treatment planning for prostate cancer in a blinded, head-to-head study with full integration into the clinical workflow. ML- and human-generated RT treatment plans were directly compared in a retrospective simulation with retesting (n = 50) and a prospective clinical deployment (n = 50) phase. Consistently throughout the study phases, treating physicians assessed ML- and human-generated RT treatment plans in a blinded manner following a priori defined standardized criteria and peer review processes, with the selected RT plan in the prospective phase delivered for patient treatment. Overall, 89% of ML-generated RT plans were considered clinically acceptable and 72% were selected over human-generated RT plans in head-to-head comparisons. RT planning using ML reduced the median time required for the entire RT planning process by 60.1% (118 to 47 h). While ML RT plan acceptability remained stable between the simulation and deployment phases (92 versus 86%), the number of ML RT plans selected for treatment was significantly reduced (83 versus 61%, respectively). These findings highlight that retrospective or simulated evaluation of ML methods, even under expert blinded review, may not be representative of algorithm acceptance in a real-world clinical setting when patient care is at stake.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. McIntosh C, Conroy L, Tjong MC, et al. Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer. Nat Med. 2021. PMID: 34083812. doi:10.1038/s41591-021-01359-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。